Conventional pharmacological treatment
ApprovedSmall molecule
Conventional pharmacological treatment is one of 45 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
149 competitors in Obstructive Sleep Apnea
#DrugCompanyPhaseTrials
1Asmanex
NovartisPhase 3
Foundayo
Eli LillyPhase 3
Mounjaro
Eli LillyPhase 3
Farxiga
AstraZenecaPhase 3
MS Contin
Merck & Co.Phase 3
Lunesta
Akero TherapeuticsPhase 3
MS Contin
HHikma Pharmaceuticals LLC
Phase 3
Ketalar
AAultman Health Foundation
Phase 3
Advil
KKenvue Brands
Phase 3
Imovane
TTaisho Pharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details